Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
Authors' conclusion
Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
Study context
- Population
- Cases of suspected non-islet cell tumor hypoglycemia (NICTH); NICTH confirmed by detection of big IGF-II in serasuspected NICTH
- Participants
- 145 cases
- Comparison
- Serum miR-483-5p vs serum IGF-II vs IGF-II to IGF-I ratio for diagnosis of NICTH
- Outcome
- Diagnostic ability for NICTH (ROC curve analysis)
Performance
As reported in the abstract
NICTH confirmed by big IGF-II in sera
100 out of 145 cases
Further findings
Serum miR-483-5p after surgical tumor resection · postoperative
- Serum miR-483-5p decreased significantly with disappearance of big IGF-II after resection (25 surgical cases)
Tissue miR-483-5p and −3p expression, resected solitary fibrous tumors (SFTs) vs surgical margins
- Significantly higher in resected SFT tissues than in surgical margins (11 surgical cases)
Original publication
Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia. J Clin Endocrinol Metab. Published 17 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →